Search the Newsreel

Does Bristow’s Profitable Q2 And Dividend Hike Change The Bull Case For Bristow Group (VTOL)?

Bristow Group Inc. (VTOL) reported a profitable Q2 2026 with sales of US$411.76 million and net income of US$21.15 million, alongside declaring a quarterly cash dividend of US$0.125 per share. While these results highlight management's confidence in cash generation, the article notes that rising …

Bristol-Myers Squibb Co (BMY) Aktienanalyse & Prognose

Noticias de acciones de Bristol-Myers Squibb Co (BMY)

The Bull Case For Bristol Myers Squibb (BMY) Could Change Following Expanded Schrödinger Bunsen AI Partnership

Bristow Group (VTOL) Stock Faces Margin Questions After 7% Drop

Bristow Group (VTOL) saw its stock drop 7% despite solid Q2 2026 revenue and EPS, signaling investor concern over narrowing margins and contract-related "growing pains." While revenue increased, net income and basic EPS fell significantly year-over-year, largely due to higher personnel and transition costs …

What the AstraZeneca-BMS rumors reveal about pharma megamergers

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb, which would have created a $400 billion pharmaceutical giant, were quickly disputed. While AstraZeneca's strong pipeline makes a merger less appealing for them, Bristol Myers Squibb could benefit due to impending patent expirations …

Bristow Group Inc (VTOL) (Q2 2026) Earnings Call Highlights: Strong OES Performance Drives ...

Bristow Group Inc. (VTOL) reported strong Q2 2026 earnings, with total revenues up $23.1 million sequentially, driven by higher utilization in Other Services and increased fuel revenues in Offshore Energy Services (OES). The company affirmed its full-year 2026 revenue and Adjusted EBITDA guidance, highlighting …

Bristow Group (NYSE:VTOL) Shares Down 7.9% on Disappointing Earnings

Bristow Group (NYSE:VTOL) shares dropped 7.9% after the company reported quarterly earnings of $0.70 per share, missing analyst estimates of $0.89, despite revenue slightly exceeding expectations at $411.75 million. The company declared a quarterly dividend of $0.125 per share, payable August 28th to shareholders …

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition

Rumors of a potential AstraZeneca-Bristol Myers Squibb merger, despite being disputed, highlight a fundamental shift in pharmaceutical competition. The article suggests that future success in the industry will depend not just on scientific innovation, but on integrated capabilities including AI, resilient manufacturing, and diversified …

Bristol Myers Squibb (BMY) Stock Looks Reasonable Below Fair Value

CPI | AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation

AstraZeneca Plc and Bristol Myers Squibb Co. have dismissed speculation regarding a potential merger, stating they are not engaged in such discussions. This clarification came after an earlier report by the Financial Times suggested talks were underway for a $400 billion deal, which caused …

Bristow Group Boosts Q2 Results, Acquires Berry Aviation

Bristow Group (VTOL) reported a strong Q2 2026, with revenues increasing to $411.8 million and net income reaching $21.2 million, driven by growth in Offshore Energy Services. The company also strategically acquired Berry Aviation in July, expanding its Government Services and affirming its 2026 …

Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report

A senior source has denied any ongoing or historical discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting earlier speculation about a nearly $400 billion deal. The denial follows initial reports that caused AstraZeneca's shares to drop, with the subsequent denial …

No deal between AstraZeneca and BMS, senior source insists: Reuters

Reuters has reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb are false, according to a senior source close to the matter. This news deflates widespread speculation about what could have been the largest pharmaceutical deal in history, valued at approximately …

Why Is Bristow Group (VTOL) Dropping 5.3%?

Bristow Group Inc. (VTOL) shares dropped 5.3% to $45.20 after its Q2 2026 earnings report, despite posting $0.70 earnings per share and $411.8 million in revenue. The market's negative reaction suggests these figures fell short of investor expectations, reflecting headwinds in the offshore energy …

Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks

A senior source close to the matter denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks, contradicting earlier reports of a potential $400 billion combination. This denial comes after AstraZeneca's shares dropped following the initial reports, while Bristol Myers Squibb's stock …

Bristow posts higher Q2 revenue & affirms 2026 outlook

Bristow Group reported a significant increase in Q2 2026 revenue to $412m, up from $389m in Q1, and affirmed its full-year 2026 outlook for total revenue and adjusted EBITDA. The company also completed its acquisition of Berry Aviation Inc., which is expected to strengthen …

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

A senior source close to the matter has stated that there are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, dispelling recent reports of a mega deal. AstraZeneca's shares initially slid after the Financial Times reported on potential talks …

Bristow Group Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:VTOL) 2026-08-05

This article presents the slide deck published by Bristow Group Inc. in conjunction with their 2026 Q2 earnings call. The company reported an EPS of $1.28, beating estimates by $0.44, and revenue of $411.76M, a 9.38% year-over-year increase, beating by $3.78M. The content is …

‘No discussions’ ongoing for AstraZeneca-BMS merger: Reuters

Reuters reported that there are no ongoing discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting an earlier Financial Times report. The Financial Times report had caused AstraZeneca's stock to drop, while the Reuters news led to a rebound for AZ …

Bristol-Myers falls on report there are no talks going on with AstraZeneca

Bristol-Myers Squibb's stock fell 1.4% in premarket trading following a report that there are no ongoing discussions with AstraZeneca regarding a potential deal. Conversely, AstraZeneca's shares rose by 5.6% after the news. The report explicitly stated that no deal ever existed between the two …

Argus Upgrades Bristol-Myers Squibb to Buy From Hold, Price Target is $75

Argus has upgraded Bristol-Myers Squibb (BMY) to a "Buy" rating from "Hold," setting a new price target of $75. The company currently holds an average rating of "overweight" with a mean price target of $66 among analysts. The full MT Newswires article with further …

Did Q2 Profit and Steady Dividend Payout Just Shift Bristow Group's (VTOL) Investment Narrative?

Bristol-Myers Squibb Co (BMY) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Bristow Group (NYSE: VTOL) grows Q2 revenue and buys Berry Aviation

Bristow Group (NYSE: VTOL) reported strong Q2 2026 financial results with increased revenues, net income, Adjusted EBITDA, and Free Cash Flow compared to Q1 2026. The company also announced the completion of its $105 million all-cash acquisition of Berry Aviation, which is expected to …

Bristow Group’s (NYSE:VTOL) Q2 CY2026 Sales Top Estimates, Guides for Strong Full-Year Sales

Bristow Group (NYSE:VTOL) reported Q2 CY2026 results with revenues exceeding market expectations and strong full-year sales guidance, though GAAP EPS missed estimates. The company's revenue increased by 9.4% year-on-year to $411.8 million, and its full-year revenue guidance surpassed analyst estimates by 2.6%. The report …

Bristow Group (VTOL) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

Bristow Group (VTOL) Lags Q2 Earnings Estimates

Bristow Group (VTOL) reported Q2 earnings of $0.7 per share, missing the Zacks Consensus Estimate of $0.84 per share, and revenues of $411.76 million, slightly exceeding the consensus. Despite outperforming the market year-to-date, the company has only surpassed EPS estimates once in the last …

Bristow Group faces earnings test seeking rebound from Q1 miss By Investing.com

Bristow Group is set to report its second-quarter earnings, with analysts anticipating a significant rebound after a sharp first-quarter earnings miss. Investors will be focused on the company's ability to demonstrate improved operational efficiency and profitability, particularly within its Offshore Energy Services segment, amidst …

AstraZeneca and Bristol Myers Squibb Held Merger Talks | PharmExec

AstraZeneca and Bristol Myers Squibb recently held discussions about a potential merger that would create the world's largest pharmaceutical company by revenue, with a combined market capitalization of nearly $400 billion. The report, though unconfirmed by either company, led to a drop in AstraZeneca …

Bristow Group (VTOL) Dividend Holds Attention As Fair Value Narrative Stays In Focus

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’

Analysts are describing a potential merger between AstraZeneca and Bristol Myers Squibb as "odd," despite its potential to create a major cancer-drug powerhouse. The Financial Times reported early-stage talks, leading to AstraZeneca shares closing lower and Bristol Myers Squibb remaining flat. This merger would …

Bristol Myers Squibb, AstraZeneca reportedly weigh $400B merger

U.K. drugmaker AstraZeneca and New Jersey-based Bristol Myers Squibb are reportedly in early-stage talks for a potential $400 billion merger. If successful, this tie-up would create the world’s fourth-largest drugmaker by market value and the largest by revenue, uniting their strengths in oncology, immunology, …

Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?

Bristow Group (NYSE:VTOL) Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Bristow Group (VTOL) reported Q2 earnings of $0.7 per share, missing the Zacks Consensus Estimate of $0.84 per share, and revenues of $411.76 million, slightly exceeding the consensus. Despite outperforming the market year-to-date, the company has only surpassed EPS estimates once in the last …